$42M in, Flag­ship star­tups merge in­to one im­muno-mi­cro­bio­me plat­form with mul­ti­ple tar­gets

What hap­pens when you com­bine two star­tups with a nov­el take on revving up and slow­ing down the im­mune sys­tem? You get a new com­pa­ny called Evelo Bio­sciences with its own twist on two hot fields: im­muno-on­col­o­gy and the mi­cro­bio­me.

“We each ID’d bac­te­ria and bac­te­r­i­al com­bi­na­tions hav­ing a pro­found im­pact on the im­mune sys­tem, but from dif­fer­ent di­rec­tions,” says Sim­ba Gill, the CEO of the com­bined op­er­a­tion, which is fold­ing the small­er Epi­va Ther­a­peu­tics in­to Evelo. Both were seed com­pa­nies start­ed in Flag­ship Ven­ture­Labs, spend­ing more than two years in stealth mode un­der the VC’s wing, where Gill is al­so a part­ner on the ven­ture side.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.